I have set a goal for myself - to create a pharmaceutical homeland - when the geographical boundaries within the framework of a business project are erased and one company operates on the territory of several states with common standards and culture. There is still a lot of work ahead. We plan to continue our investments, expand the portfolio of medicines in order to further contribute to the economy of the state and the development of the healthcare system.
Jiri Urbanec

CEO of SANTO

708
million
tablets
255
million
capsules
7,5
million
sachets
135
tons
of tablet mass by wet granulation
46.7
million
vials with cephalosporin antibiotics
15.5
million
vials with penem/mycin antibiotics
8.4
tons
of million vials with non-sterile liquid dosage forms.
250
million
injection ampoules
2.9
million
infusion bags and bottles

About us

SANTO is a part of the international Polpharma Group. We produce over 240 names of medicines in 12 pharmacotherapeutic groups for the treatment of diseases in various therapeutic areas. .

The production of medicines complies with international GMP and GDP quality standards. We are engaged in drug development, technology transfer from the Polpharma Group, manufacturing, packaging and transportation of medicines. The product portfolio is regularly updated and expanded.

The efficacy of our products has been proven by independent laboratory tests. Our medicines are used for the treatment of various diseases: they are prescribed by physicians and chosen by patients.

The history of the company's creation
1882
Plant establishment
The SANTO plant is one of the oldest pharmaceutical enterprises in Kazakhstan. It was founded in 1882 by merchants Ivanov and Savenkov as a plant for the production of the Santonin drug - an anthelmintic agent based on wormwood (Artemisia cina). Today, a sprig of wormwood adorns the coat of arms of Shymkent, for which the opening of a pharmaceutical enterprise was a powerful impetus for development.

1917-1991
Working in the USSR period
During the Soviet period, the plant was the largest producer of pharmaceutical substances from raw plant materials and a manufacturer of narcotic agents.

1993
Reorganization into Chimpharm JSC
Commencement of the pharmaceutical production large-scale modernization in accordance with the international GMP quality standard within the framework of the implementation of an investment project worth about 108 million US dollars.

2011
Merger into Polpharma Group
Commencement of the pharmaceutical production large-scale modernization in accordance with the international GMP quality standard within the framework of the implementation of an investment project worth about 108 million US dollars.

2014
Launching production of medicines in ampoules and infusions
A new production workshop was opened within the framework of the FIID State Program. At the moment, parenteral solutions of large and small dosages are produced in this workshop.

2016
Launching production of antibiotic powders (GMP)
A new workshop for the production of antibiotic powders (cephalosporins and penems/mycins) complies with the international GMP standard. The production is arranged on two separate lines.

2017
Launching production of oral solid dosage forms (GMP)
A new workshop for the production of oral solid dosage forms by dry granulation method was launched as part of the plant’s 135th anniversary celebration.

2018
Commencement of production of oral liquid dosage forms (GMP) as well as modernization of the warehouse (GDP)
As part of the product range expansion, a new manufacturing field was introduced - the production of oral liquid dosage forms. GMP recertification was successfully passed, and a GDP compliance certificate was obtained for the modernized pharmacy warehouse of the plant.

2019
Commencement of production of oral solid dosage forms by wet granulation method (GMP); the opening of the Digital Engineering and Education Center as well as a sculpture named “Looking into the Future” at the SANTO plant.

2020
Winning in the BEST RX CORPORATION OF KAZAKHSTAN 2020 nomination
For the first time, SANTO became a winner of IQVIA RX & CONSUMER HEALTH AWARDS 2020 in the pharmaceutical market of Kazakhstan in the BEST RX CORPORATION KAZAKHSTAN 2020 nomination.

2021
Winning the PARYZ Republican Contest
For the first time, SANTO became a winner of the Paryz-2021 Republican Contest on Social Responsibility in the nomination “The Best Socially Responsible Enterprise”.

2021
Winning the EURASIAN PHARMA AWARD Contest
For the first time, SANTO became the winner of the Eurasian Pharma Award-2021 Contest in the nomination “Local Company of the Year”.

Our mission and values

Helping people live healthy live in a healthy world
Culture as an accelerator of the company development
WE ACT
With ownership
As one
With openness
Уважение
Appreciation
Сотрудничество
Fairness
Ответственность
Responsibility
Солидарность
Solidarity
Сотрудничество
Collaboration

SANTO’s academic program

In 2013, we launched our major education project - SANTO’s academic program- for the purpose of pharmaceutical industry quality improvement to international standards.
More details